Genelabs Technologies
Get verified emails for Genelabs Technologies employees
About Genelabs Technologies
|
|
|
11-50 employees
View all
|
|
biotechnology
|
|
US
|
|
Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.
|
Genelabs Technologies Email Format
The widely used Genelabs Technologies email format is {f}{last}@genelabs.com (e.g. [email protected]), which is used 75.00% of the time.
| Genelabs Technologies Email Formats | Example Email Formats | Percentage |
|---|---|---|
| {f}{last} | [email protected] |
75.00%
|
Genelabs Technologies Alternatives
Frequently Asked Questions about Genelabs Technologies
What is Genelabs Technologies email format?
The widely used Genelabs Technologies email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
What is Genelabs Technologies customer service number?
To contact Genelabs Technologies customer service number in your country click here to find.
Who is the CEO of Genelabs Technologies?
Fred Driscoll is the CEO of Genelabs Technologies.
Genelabs Technologies Staff Directory
Search Genelabs Technologies Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Search Portal
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.
